Automatic Website Traffic RSS

Antiarrhythmic Therapy Following Ablation of Atrial Fibrillation

Antiarrhythmic drugs (AADs) are often used after ablation for atrial fibrillation (AF); the drugs employed vary, but most common are the drugs that were unsuccessful prior to ablation since it ... read more

Predicting cardiac arrhythmia 30 minutes before it happens

Atrial fibrillation is the most common cardiac arrhythmia worldwide with around 59 million people concerned in 2019. This irregular heartbeat is associated with increased risks of heart failure, ... read more

Smartwatch AI predicts atrial fibrillation 30 minutes before it arrives

AI trained on simple heart rate data can predict an episode of the most common heart rhythm disorder, atrial fibrillation, 30 minutes in advance, new research has shown. With plans for it to be ... read more

Deep learning predicts heart arrhrythmia 30 minutes in advance

Atrial fibrillation is the most common cardiac arrhythmia worldwide with around 59 million people concerned in 2019. This irregular heartbeat is associated with increased risks of heart failure, ... read more

Novel antiarrhythmic agent shows promise in Phase III trial

Atrial fibrillation is the most common type of cardiac arrhythmia, and is a common cause of stroke and heart failure. Currently, there is a major unmet need for drugs that are capable of ... read more

Antiarrhythmic drugs in the treatment of ARVC

However, the efficacy of antiarrhythmic agents has not been rigorously evaluated in patients with ARVC, and limited data are available to support such use of these drugs. The Multidisciplinary ... read more

Thermedical Successfully Completes Feasibility Study for Treating Cardiac Arrhythmias Using Pulsed Field Ablation in Combination with SERF Ablation

Thermedical®, a developer of advanced thermal-ablation systems to treat ventricular arrhythmias, announced today that it has completed a feasibility study utilizing Pulsed Field Ablation (PFA) therapy ... read more

Rythmol Sr

Based on findings, it is prudent to consider any Class IC antiarrhythmic to have significant proarrhythmic risk in patients with structural heart disease. Antiarrhythmic agents should generally be ... read more

International experts agree on standards for catheter ablation of atrial fibrillation

An international consensus statement on how to treat atrial fibrillation with catheter or surgical ablation has been published in EP Europace and presented at EHRA 2024. Lead author Dr. read more

Treating gum disease during AFib blanking period could reduce recurrence risk

Study evaluates whether treating periodontitis during the blanking period after atrial fibrillation (AF) ablation reduces AF recurrence, revealing that comprehensive periodontal care may significantly ... read more

Global Andersen Tawil Syndrome Treatment Market Set to Flourish, Expected to Reach US$ 4.2 Billion with a CAGR of 8.26% by 2033

The global  Andersen-Tawil syndrome (ATS) treatments market  is anticipated to experience significant growth in the coming decade, reaching an impressive US$4.2 billion by 2033. This represents a ... read more

Antiarrhythmic Therapy Following Ablation of Atrial Fibrillation

The use of AADs in the early period after AF aims to reduce early recurrence of atrial arrhythmia or the occurrence of macroreentrant LA tachycardia, during the 'blanking period'. Early recurrence ... read more